Singapore: DIA, the premier organization dedicated to knowledge exchange that fosters innovation to raise the level of health and well-being worldwide, has appointed Dr Ling Su as the president to its board of directors. Dr Su has served as chair of the DIA Provisional Advisory Council, China, and also received the DIA Outstanding Service Award in 2000.

Dr Su is presently the senior vice president and head of development, greater China region, Beijing, for Novartis Pharma. He is also an adjunct professor in the school of pharmacy at Fudan University, Shanghai. Dr Su brings more than 20 years of experience to DIA, specifically in the areas of regulatory affairs, clinical research and development, R&D strategies, pharmacovigilance, pharmacoepidemiology and outcomes research.

Dr Su, while speaking about his appointment, said that, "Through my years of service in the industry, as an active DIA volunteer for 20 years, and now as DIA board president, I plan on sharing my insight to help DIA and the industry overcome the challenges that we collectively face."

DIA is a neutral, global, professional, and member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products.